Le Lézard
Classified in: Health
Subject: SVY

PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities


NEW YORK, Oct. 6, 2017 /PRNewswire/ -- PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities

Summary

Read the full report: https://www.reportlinker.com/p05134501


Immuno-Oncology (IO) is uniquely positioned to become the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and other targeted treatments. In order to assist our clients with navigating the burgeoning amount information arising as a result of the rapidly growing field of IO clinical research, GlobalData is offering a comprehensive analysis of both pipeline and marketed active immunity IO therapies.

Scope
Key Topics Covered -
- Immune Checkpoint Modulators - Trends in Clinical Trial Development
- Competitive Assessment of Marketed PD-(L)1 Checkpoint Modulators
- Emergence of New Immune Checkpoint Targets
- Clinical and Commercial Opportunities for Highly Anticipated CAR Cell Therapies
- Cell Vaccines: Steady Development Stimulated by Prior IO Success
- Promising IO-IO Combinations Utilizing Oncolytic Viruses

Reasons to buy
- The PharmaFocus consists of a highly-visual slide deck that is intended to facilitate the dissemination of aggregated data and insights from analyses of over 800 IO products that are either marketed or in Phase I-III of clinical development.
- Types of graphical analyses include - Cumulative Plots, Aggregated Bubble Plots, Pie Charts, Matrix Analyses
- Unique, actionable insights applicable to IO drugs in five major categories: Immune Checkpoint Modulators, Cellular Immunotherapies, Oncolytic Viruses, Peptide Vaccines, and Bispecific T-Cell Engagers are provided in this report.
- Analysis of over 4000 clinical trials enrolling patients with 18 solid tumors and eight hematological cancers are included.

Read the full report: https://www.reportlinker.com/p05134501

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

https://www.reportlinker.com


__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 08:15
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it will be attending the LSX World Congress (29-30 April) and presenting at Bio?quity Europe (12-14 May). The...

at 08:15
Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety...

at 08:15
Nuvation Bio Inc. , a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms....

at 08:10
Edgewise Therapeutics, Inc. , a leading muscle disease biopharmaceutical company, today announced that the Company will present data on EDG-7500 at the American College of Cardiology's Annual Scientific Session (ACC.24). EDG-7500 is a first-in-class...

at 08:05
Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of a new Human Pangenome Spike-in for the Twist Exome 2.0 panel developed...

at 08:05
Bio-K Plus, a Kerry Company, pioneer in the probiotic sector, is pleased to announce the launch of its new functional drinkable probiotic, the Extra Stress Support with Sensoril®....



News published on and distributed by: